Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayer, Yang [1 ]
Wu, Qi [1 ]
Wang, Qin [1 ]
Lundy, Steve K. [1 ]
Dowling, Catherine [1 ]
Segal, Benjamin Matthew M. [1 ]
Fox, David [1 ]
Wallstroem, Erik [2 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P011
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayers, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steven
    Segal, Benjamin
    Wallstrom, Wallstrom
    NEUROLOGY, 2016, 86
  • [2] Baseline immunological profile in secondary progressive multiple sclerosis patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steve K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 13 - 13
  • [3] Baseline Immunophenotyping and Gene Expression Analysis in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Mao, Guangmei
    Lundy, Steven K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 68 - 68
  • [4] Comparative Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Mao, Guangmei
    Dowling, Catherine
    Lundy, Steven
    Wallstrom, Erik
    Fox, David
    NEUROLOGY, 2017, 88
  • [5] THE MS-STAT TRIAL: A PHASE II TRIAL OF HIGH-DOSE SIMVASTATIN FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: BASELINE TRIAL PROFILE
    Chataway, J.
    Anderson, V.
    Chan, D.
    Frost, C.
    Hunter, K.
    Kallis, C.
    Greenwood, J.
    Schuerer, N.
    Alsanousi, A.
    Nicholas, R.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (11): : E55 - E55
  • [6] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Lam, Elaine
    Pohlmann, Harold
    Zhang-Auberson, Lixin
    Dandekar, Atul
    Wallstroem, Erik
    NEUROLOGY, 2013, 80
  • [7] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Lam, E.
    Pohlmann, H.
    Zhang-Auberson, L.
    Dandekar, A.
    Wallstrom, E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 927 - 928
  • [8] Immunological aspects of secondary progressive multiple sclerosis
    Weiner, LP
    Kachuck, NJ
    Gilmore, W
    Lund, B
    MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (01) : 83 - 84
  • [9] Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis
    McAdams, Matthew
    Stankiewicz, James M.
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [10] Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Bhasin, Priya
    Arnould, Sophie
    Sidorenko, Tatiana
    Wallstroem, Erik
    NEUROLOGY, 2016, 86
12345